MDK and ovarian carcinoma: Its downstream targets include anti-apoptotic proteins such as Bcl-2, and MDK also facilitates drug efflux by upregulating ABC transporters, such as MDR1 and ABCG2, leading to multidrug resistance in gastric, leukemia, and ovarian cancer models.